The company plans to add 1700 beds by FY27 through the organic route
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
New leadership team announced at NATHEALTH Annual General Meeting 2024
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
The company had earlier announced about the approval received from the MHRA for Liraglutide
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Subscribe To Our Newsletter & Stay Updated